These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28950022)

  • 1. Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project.
    Vaccher SJ; Grulich AE; Haire BG; Conway DP; Poynten IM; Ooi C; Foster R; Templeton DJ; Zablotska IB;
    PLoS One; 2017; 12(9):e0185398. PubMed ID: 28950022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.
    Grulich AE; Jin F; Bavinton BR; Yeung B; Hammoud MA; Amin J; Cabrera G; Clackett S; Ogilvie E; Vaccher S; Vickers T; McNulty A; Smith DJ; Dharan NJ; Selvey C; Power C; Price K; Zablotska I; Baker DA; Bloch M; Brown K; Carmody CJ; Carr A; Chanisheff D; Doong N; Finlayson R; Lewis DA; Lusk J; Martin S; Ooi C; Read P; Ryder N; Smith D; Tuck Meng Soo C; Templeton DJ; Vlahakis E; Guy R;
    Lancet HIV; 2021 Aug; 8(8):e486-e494. PubMed ID: 34217426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17.
    Holt M; Lea T; Mao L; Kolstee J; Zablotska I; Duck T; Allan B; West M; Lee E; Hull P; Grulich A; De Wit J; Prestage G
    Lancet HIV; 2018 Aug; 5(8):e448-e456. PubMed ID: 29885813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Willingness to use and have sex with men taking HIV pre-exposure prophylaxis (PrEP): results of online surveys of Australian gay and bisexual men, 2011-2015.
    Holt M; Lea T; Schmidt HM; Kolstee J; Ellard J; Murphy D; Truong HH; de Wit J
    Sex Transm Infect; 2017 Sep; 93(6):438-444. PubMed ID: 28108701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project.
    Vaccher SJ; Marzinke MA; Templeton DJ; Haire BG; Ryder N; McNulty A; Foster R; Grulich AE; Zablotska IB; ;
    AIDS Behav; 2019 May; 23(5):1287-1296. PubMed ID: 30523489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual health clinics in Auckland, New Zealand.
    Azariah S; Saxton P; Franklin R; Forster R; Werder S; Jenkins R
    BMJ Open; 2019 Jun; 9(6):e026363. PubMed ID: 31248921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics of gay and bisexual men in a HIV pre-exposure prophylaxis demonstration project with equity quotas in Auckland, New Zealand.
    Saxton PJW; Azariah S; Franklin RA; Forster RF; Werder SF; Jenkins R; Myers JM; Rich JG; Te Wake WP; Fisher MD
    Sex Health; 2019 Feb; 16(1):47-55. PubMed ID: 30274568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Attitudes to and the Use of HIV Pre-exposure Prophylaxis by Australian Gay and Bisexual Men, 2011-2017: Implications for Further Implementation from a Diffusion of Innovations Perspective.
    Holt M; Lea T; Bear B; Halliday D; Ellard J; Murphy D; Kolstee J; de Wit J
    AIDS Behav; 2019 Jul; 23(7):1939-1950. PubMed ID: 30539496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explicit Relationship Agreements and HIV Pre-exposure Prophylaxis Use by Gay and Bisexual Men in Relationships.
    MacGibbon J; Bavinton BR; Drysdale K; Murphy D; Broady TR; Kolstee J; Molyneux A; Power C; Paynter H; de Wit J; Holt M
    Arch Sex Behav; 2023 Feb; 52(2):761-771. PubMed ID: 35939159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High HIV risk and syndemic burden regardless of referral source among MSM screening for a PrEP demonstration project in Toronto, Canada.
    Wilton J; Noor SW; Schnubb A; Lawless J; Hart TA; Grennan T; Fowler S; Maxwell J; Tan DHS
    BMC Public Health; 2018 Feb; 18(1):292. PubMed ID: 29486737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomedical HIV Protection Among Gay and Bisexual Men Who Use Crystal Methamphetamine.
    Hammoud MA; Jin F; Maher L; Bourne A; Haire B; Saxton P; Vaccher S; Lea T; Degenhardt L; Prestage G
    AIDS Behav; 2020 May; 24(5):1400-1413. PubMed ID: 31758350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increases in HIV Testing Frequency in Australian Gay and Bisexual Men are Concentrated Among PrEP Users: An Analysis of Australian Behavioural Surveillance Data, 2013-2018.
    Bavinton BR; Grulich AE; Broady T; Keen P; Mao L; Patel P; Chan C; Prestage GP; Holt M
    AIDS Behav; 2020 Sep; 24(9):2691-2702. PubMed ID: 32162094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of HIV Pre-exposure Prophylaxis (PrEP) Associated With Lower HIV Anxiety Among Gay and Bisexual Men in Australia Who Are at High Risk of HIV Infection: Results From the Flux Study.
    Keen P; Hammoud MA; Bourne A; Bavinton BR; Holt M; Vaccher S; Haire B; Saxton P; Jin F; Maher L; Grulich AE; Prestage G
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):119-125. PubMed ID: 31935203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The estimated number of potential PrEP users among gay-identifying men who have sex with men in Australia.
    Zablotska IB; Gray R; Whittaker B; Holt M; Wright E; Prestage G; O'Donnell D; Grulich AE
    PLoS One; 2018; 13(10):e0204138. PubMed ID: 30335758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDE.
    Zablotska IB; Vaccher SJ; Bloch M; Carr A; Foster R; Grulich AE; Guy R; McNulty A; Ooi C; Pell C; Poynten IM; Prestage G; Ryder N; Templeton D;
    AIDS Behav; 2019 Jul; 23(7):1780-1789. PubMed ID: 30284653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.